Exact (Xylocor)

Exact (Xylocor)

The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options.

Please use this link for further information:

Primary Investigator: Timothy Henry

Enrolling

Disclaimer: Patients must have an existing, documented diagnosis to be entered into some trials.
Copyright © 2024 All rights reserved.

Web Design by TBH Creative